<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259008</url>
  </required_header>
  <id_info>
    <org_study_id>2001902</org_study_id>
    <nct_id>NCT04259008</nct_id>
  </id_info>
  <brief_title>Safety of Manganese Restriction in Neonatal Parenteral Nutrition</brief_title>
  <official_title>Safety of Manganese Restriction in Neonatal Parenteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants will be &lt;= 32 weeks gestational age (GA) neonates randomized to parenteral
      nutrition (PN) prepared with standard dose trace elements or to PN prepared with standard
      trace elements minus manganese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Very preterm neonates &lt;= 32+6 weeks GA receiving PN will be randomized to receive their PN
      prepared with standard trace elements containing 5 mcg/kg/day of manganese, or to PN prepared
      with no added manganese. Randomization assignment will be double masked. All participants
      will have whole blood manganese measurements at baseline, at 2 weeks of postnatal age, and at
      8 weeks postnatal age. Because manganese is present as a contaminant in many of the
      ingredients used to prepare neonatal PN, this study hypothesizes that neonates randomized to
      no added manganese in their PN will maintain whole blood manganese concentrations above the
      lower limit of normal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants randomized to standard trace element dose in parenteral nutrition vs. omission of manganese.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole Blood Manganese</measure>
    <time_frame>Baseline</time_frame>
    <description>concentration of manganese in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole Blood Manganese</measure>
    <time_frame>2 weeks of age</time_frame>
    <description>concentration of manganese in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole Blood Manganese</measure>
    <time_frame>8 weeks of age</time_frame>
    <description>concentration of manganese in blood</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Infant, Newborn, Disease</condition>
  <arm_group>
    <arm_group_label>Standard neonatal trace elements</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parenteral nutrition containing 5 mCg/kg/day manganese from &quot;Multitrace-4 Neonatal.&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manganese-free neonatal trace elements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parenteral nutrition containing the same trace element doses as &quot;Multitrace-4 Neonatal&quot; minus manganese.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Manganese omission</intervention_name>
    <description>Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.</description>
    <arm_group_label>Manganese-free neonatal trace elements</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>5 mCg/kg/day manganese from &quot;Multitrace-4 Neonatal.&quot;</intervention_name>
    <description>5 mCg/kg/day manganese from &quot;Multitrace-4 Neonatal.&quot;</description>
    <arm_group_label>Standard neonatal trace elements</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inborn admissions to the SHARP Mary Birch Hospital for Women and Newborns neonatal
             intensive care unit.

          -  Less than or equal to 32+6 weeks gestational age.

          -  Initiated on parenteral nutrition as decided by their attending neonatologist.

        Exclusion Criteria:

          -  Continuous exposure to routine care PN containing standard trace element for â‰¥ 4
             hours.

          -  Congenital liver disease.

          -  Moribund status or imminent death.

          -  Any condition that in the judgment of the investigator or attending physician provider
             precludes participation because it could affect subject safety.

          -  Lack or refusal of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason B Sauberan, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason B Sauberan, PharmD</last_name>
    <phone>858-939-6307</phone>
    <email>jason.sauberan@sharp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcie Portillo</last_name>
    <phone>858-939-4112</phone>
    <email>marcie.portillo@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women and Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason B Sauberan</last_name>
      <phone>858-939-4299</phone>
      <email>Jason.sauberan@sharp.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>Jason Sauberan, PharmD</investigator_full_name>
    <investigator_title>Clinical Research Pharmacist</investigator_title>
  </responsible_party>
  <keyword>manganese, parenteral nutrition, neonate, preterm, safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Manganese</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Immediately after publication</ipd_time_frame>
    <ipd_access_criteria>Anyone</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

